New Rubella Virus-Like Particles Released

The Native Antigen Company have announced the release of its Rubella virus-like particles (VLPs). The Rubella VLPs are a unique product in its new range of Rubella virus reagents, adding to the Company’s extensive selection of recombinant VLPs that offer researchers a reliable source of high-quality reagents for immunoassay development and manufacturing.

The Native Antigen Company specialises in the isolation and purification of native antigens and recombinant proteins from viral and bacterial pathogens. The first-to-market Rubella VLPs are expressed as recombinant proteins in the Company’s proprietary mammalian cell expression system. Recombinant expression of the Rubella structural polyprotein in HEK293 cells enables reliable and cost-effective production of high-quality VLPs, helping to ensure researchers achieve consistent and accurate results throughout immunoassay development and scale-up manufacturing. The Native Antigen Company also offers Rubella antigens, monoclonal antibodies and ELISAs for use in a wide range of research applications.

Dr Andy Lane, Commercial Director, The Native Antigen Company, said: “We are committed to expanding our product portfolio of reagents to facilitate cutting-edge vaccine and diagnostics research for infectious disease. Our reputation for delivering high-quality VLPs is growing and the addition of the Rubella VLPs to our new Rubella virus range means we are now able to offer researchers a consistent, well-defined and cost-effective alternative to current native Rubella products on the market, which are often difficult to produce and increasingly expensive.”

Rubella virus is the causative agent of a highly contagious acute self-limiting and generally mild disease known as Rubella or German measles, predominantly affecting children and young adults. However, when contracted during the first trimester of pregnancy, Rubella poses a significant health risk to the foetus. Rubella infection and vaccination provide >95% chance of developing lifetime immunity.